These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
367 related items for PubMed ID: 15691271
1. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Caccamo L, Romeo R, Rossi G, Maggioni M, Radice F, Lunghi G, Colombo M, Fassati LR. Transpl Int; 2005 Feb; 18(2):186-92. PubMed ID: 15691271 [Abstract] [Full Text] [Related]
2. Factors associated with viral breakthrough in lamivudine monoprophylaxis of hepatitis B virus recurrence after liver transplantation. Chan HL, Chui AK, Lau WY, Chan FK, Wong ML, Tse CH, Rao AR, Wong J, Sung JJ. J Med Virol; 2002 Oct; 68(2):182-7. PubMed ID: 12210406 [Abstract] [Full Text] [Related]
3. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients]. Yang Y, Yang Y, Zhang J, Yi HM, Lu MQ, Cai CJ, Li X, Jiang N, Xu C, Li H, Wang GS, Yi SH, Zhang JF, Jiang H, Yang Q, Chen GH. Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179 [Abstract] [Full Text] [Related]
9. Presence of intrahepatic (total and ccc) HBV DNA is not predictive of HBV recurrence after liver transplantation. Hussain M, Soldevila-Pico C, Emre S, Luketic V, Lok AS, NIH HBV-OLT Study Group. Liver Transpl; 2007 Aug; 13(8):1137-44. PubMed ID: 17663390 [Abstract] [Full Text] [Related]
12. [Relationship between hepatitis B virus YMDD mutation and serum viral DNA loadings]. Kong LH, Gao SX, Gui YP, Liu WH. Nan Fang Yi Ke Da Xue Xue Bao; 2007 Aug; 27(8):1262-3. PubMed ID: 17715043 [Abstract] [Full Text] [Related]
13. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation. Lu SC, Yan LN, Li B, Wen TF, Zhao JC, Cheng NS, Liu C, Liu J, Wang XB, Li XD, Qin S, Zhao LS, Lei BJ, Zhang XH. Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833 [Abstract] [Full Text] [Related]
14. Genotypic and phenotypic resistance: longitudinal and sequential analysis of hepatitis B virus polymerase mutations in patients with lamivudine resistance after liver transplantation. Ben-Ari Z, Daudi N, Klein A, Sulkes J, Papo O, Mor E, Samra Z, Gadba R, Shouval D, Tur-Kaspa R. Am J Gastroenterol; 2003 Jan; 98(1):151-9. PubMed ID: 12526951 [Abstract] [Full Text] [Related]
15. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Xie SB, Zhu JY, Ying Z, Zeng LJ, Chao M, Lu MQ. Transplantation; 2010 Oct 15; 90(7):786-90. PubMed ID: 20703179 [Abstract] [Full Text] [Related]
16. Evolution of wild-type and precore mutant HBV infection after liver transplantation. Torre F, Wong PY, Macartney M, Williams R, Naoumov NV. J Med Virol; 1999 Sep 15; 59(1):5-13. PubMed ID: 10440801 [Abstract] [Full Text] [Related]
18. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. Woo HY, Choi JY, Jang JW, You CR, Bae SH, Yoon SK, Yang JM, Choi SW, Han NI, Kim DG. J Med Virol; 2008 Nov 15; 80(11):1891-9. PubMed ID: 18814257 [Abstract] [Full Text] [Related]
19. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW. Hepatobiliary Pancreat Dis Int; 2008 Aug 15; 7(4):357-61. PubMed ID: 18693169 [Abstract] [Full Text] [Related]
20. Clinical and virological features of non-breakthrough and severe exacerbation due to lamivudine-resistant hepatitis B virus mutants. Suzuki F, Akuta N, Suzuki Y, Sezaki H, Arase Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Ikeda K, Kobayashi M, Matsuda M, Satoh J, Watahiki S, Kumada H. J Med Virol; 2006 Mar 15; 78(3):341-52. PubMed ID: 16419116 [Abstract] [Full Text] [Related] Page: [Next] [New Search]